Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
HYDRO-SERP "25" vs ALDOCLOR-250
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Hydrochlorothiazide inhibits the Na+/Cl- symporter in the distal convoluted tubule of the kidney, reducing sodium and chloride reabsorption and promoting diuresis. Reserpine depletes catecholamines in postganglionic sympathetic nerve endings by inhibiting the vesicular monoamine transporter, leading to reduced sympathetic outflow and vasodilation.
Aldoclor-250 is a combination of methyldopa and chlorothiazide. Methyldopa is a centrally acting alpha-2 adrenergic agonist that reduces sympathetic outflow from the brain, decreasing peripheral vascular resistance and blood pressure. Chlorothiazide is a thiazide diuretic that inhibits sodium and chloride reabsorption in the distal convoluted tubule, increasing urinary output and reducing plasma volume.
Hypertension
Hypertension (first-line or adjunctive therapy),Off-label: Management of hypertensive crisis (as part of combination therapy)
Hydrochlorothiazide 25 mg orally once daily in the morning. Maximum 100 mg/day.
250 mg orally twice daily
Reserpine: terminal elimination half-life 33-45 hours (range 30-60 hours), with clinical context of prolonged autonomic effects lasting days; hydrochlorothiazide: terminal half-life 6-15 hours (mean 10 hours).
1.5-3 hours; prolonged in renal impairment (up to 20 hours with Cr Cl <10 m L/min).
Hydrochlorothiazide is not extensively metabolized; reserpine is extensively metabolized in the liver via CYP450 enzymes.
Methyldopa: Primarily hepatic metabolism via catecholamine pathways; conjugated to sulfate and other metabolites. Chlorothiazide: Not extensively metabolized; excreted unchanged in urine.
Renal (approximately 30-50% as unchanged drug and metabolites), biliary/fecal (approximately 50-70% as metabolites, with enterohepatic recirculation noted for reserpine component).
Renal (70-80% unchanged), biliary/fecal (15-25% as metabolites); total clearance ~250 m L/min.
Reserpine: 95-98% bound to plasma proteins; hydrochlorothiazide: 60-70% bound to albumin.
25-40% bound primarily to albumin and alpha-1-acid glycoprotein.
Reserpine: Vd approximately 0.5-0.7 L/kg, indicating extensive tissue distribution and high lipophilicity; hydrochlorothiazide: Vd 0.2-0.4 L/kg, primarily confined to extracellular fluid.
0.6-1.0 L/kg; indicates distribution into total body water and some tissue binding.
Reserpine: oral bioavailability approximately 50% due to first-pass metabolism; hydrochlorothiazide: oral bioavailability 65-75%.
70-90% (oral); 100% (IV).
GFR 30-50 m L/min: 25 mg once daily. GFR 15-29 m L/min: not recommended. GFR <15 m L/min: contraindicated.
Cr Cl >50 m L/min: no adjustment; Cr Cl 10-50 m L/min: 250 mg once daily; Cr Cl <10 m L/min: 250 mg every 48 hours
Child-Pugh Class A or B: no adjustment. Child-Pugh Class C: use with caution, consider starting at 12.5 mg daily.
Child-Pugh A: no adjustment; Child-Pugh B: use with caution, reduce dose by 50%; Child-Pugh C: avoid use
Weight-based: 1-2 mg/kg/day orally divided every 12-24 hours, maximum 100 mg/day.
Not recommended for use in pediatric patients due to lack of safety and efficacy data
Start at 12.5 mg daily; monitor electrolytes and renal function; may increase to 25 mg daily if needed.
Start at lower end of dosing range; monitor renal function closely; adjust dose based on Cr Cl
None
None explicitly listed. However, methyldopa carries a warning for hepatotoxicity and hemolytic anemia; chlorothiazide carries a warning for electrolyte disturbances and hypersensitivity reactions.
May cause electrolyte imbalance (hypokalemia, hyponatremia),May exacerbate systemic lupus erythematosus,Reserpine may cause mental depression, peptic ulcer, and nasal congestion,Photosensitivity,Orthostatic hypotension with reserpine
Hepatotoxicity (methyldopa), hemolytic anemia, positive direct Coombs test, sedation, depression, bradycardia, orthostatic hypotension, electrolyte imbalance (hypokalemia, hyponatremia, hypomagnesemia), hyperuricemia, hyperglycemia, photosensitivity, lupus-like syndrome, and hypersensitivity reactions.
Anuria,Sulfonamide allergy (hydrochlorothiazide is a sulfonamide),Known hypersensitivity to hydrochlorothiazide or reserpine,Active peptic ulcer (due to reserpine),Electroconvulsive therapy (within 7 days, due to reserpine)
Active hepatic disease, history of previous methyldopa-induced liver dysfunction, hemolytic anemia associated with methyldopa, anuria, hypersensitivity to methyldopa, chlorothiazide, or sulfonamide-derived drugs, severe renal impairment (Cr Cl <30 m L/min), and concomitant therapy with MAO inhibitors.
Avoid high-sodium foods to enhance antihypertensive effect. Limit alcohol intake as it may potentiate hypotension. Grapefruit juice may alter drug metabolism; avoid excessive consumption. Maintain adequate potassium intake (bananas, oranges) unless advised otherwise by your doctor.
Avoid high-potassium foods (bananas, oranges, spinach) unless specifically advised; chlorothiazide may cause potassium loss, but methyldopa can cause potassium retention. Avoid excessive alcohol intake as it may potentiate hypotension. Take with food to reduce gastrointestinal upset. May decrease glucose tolerance; monitor in diabetic patients.
FDA Pregnancy Category D. Use of reserpine in the first trimester is associated with an increased risk of congenital malformations, including neural tube defects and cardiovascular anomalies. In the second and third trimesters, exposure may cause fetal bradycardia, hypothermia, and respiratory depression due to depletion of catecholamines. Chronic use may lead to fetal growth restriction.
FDA Pregnancy Category D. First trimester: Associated with cardiovascular defects (e.g., VSD), neural tube defects, and oral clefts. Second and third trimesters: Fetal nephrotoxicity (oligohydramnios, renal failure), premature closure of ductus arteriosus, pulmonary hypertension, and intracranial hemorrhage. Avoid in third trimester.
Reserpine is excreted into breast milk with an M/P ratio of 0.5. Due to the potential for serious adverse reactions in nursing infants, including gastrointestinal disturbances, nasal congestion, and lethargy, breastfeeding is contraindicated during reserpine therapy.
Chlorothiazide is excreted in breast milk; M/P ratio unknown. Can suppress lactation. Use only if maternal benefit outweighs potential infant risks (e.g., electrolyte disturbances, thrombocytopenia).
No pharmacokinetic studies are available to guide dosing adjustments during pregnancy; however, due to increased plasma volume and renal clearance, the effective dose may need to be increased, but this must be balanced against fetal risks. The lowest effective dose should be used and the drug should be discontinued if possible, especially during the third trimester to avoid neonatal effects.
Increased volume of distribution and GFR in pregnancy may necessitate higher doses for equivalent effect. Start at lowest effective dose; titrate based on BP response. Monitor for hypokalemia and metabolic alkalosis.
Hydro-Serp '25' contains hydrochlorothiazide 25 mg and reserpine 0.125 mg. Monitor serum potassium and magnesium; hypokalemia increases digitalis toxicity risk. Reserpine may cause mental depression; use with caution in patients with history of depression. Taper reserpine before surgery to avoid hypertensive rebound. Avoid concurrent use with MAOIs.
Aldoclor-250 is a combination of methyldopa (250mg) and chlorothiazide. Methyldopa can cause a positive direct Coombs test (10-20% of patients) which may interfere with blood cross-matching; obtain a hematocrit and Coombs test before therapy and at 6 and 12 months. Chlorothiazide may cause hypokalemia; monitor potassium and consider potassium supplementation. Onset of methyldopa is 3-6 hours; delay full effect for 48-72 hours. Avoid use in patients with active liver disease or history of previous methyldopa-induced liver dysfunction.
Take exactly as prescribed; do not discontinue abruptly.,This medication may make you dizzy or drowsy; avoid driving until you know how it affects you.,Rise slowly from sitting or lying to prevent falls from low blood pressure.,Report any mood changes, depression, or vivid dreams to your doctor.,Use sunscreen and protective clothing; this drug increases sun sensitivity.,Do not use potassium supplements or salt substitutes without asking your doctor.
Take exactly as prescribed; do not skip doses or stop suddenly.,May cause drowsiness or dizziness; avoid driving or operating machinery until you know how it affects you.,Rise slowly from sitting or lying to prevent lightheadedness.,Report any unexplained fever, jaundice, or dark urine immediately.,Use sun protection; this drug may increase sensitivity to sunlight.,Do not use potassium supplements or salt substitutes without consulting your doctor.,If you miss a dose, take it as soon as you remember unless it's near the next dose; do not double.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about HYDRO-SERP "25" vs ALDOCLOR-250, answered by our medical review team.
HYDRO-SERP "25" is a Antihypertensive Combination that works by Hydrochlorothiazide inhibits the Na+/Cl- symporter in the distal convoluted tubule of the kidney, reducing sodium and chloride reabsorption and promoting diuresis. Reserpine depletes catecholamines in postganglionic sympathetic nerve endings by inhibiting the vesicular monoamine transporter, leading to reduced sympathetic outflow and vasodilation.. ALDOCLOR-250 is a Antihypertensive Combination (Central Alpha Agonist and Thiazide Diuretic) that works by Aldoclor-250 is a combination of methyldopa and chlorothiazide. Methyldopa is a centrally acting alpha-2 adrenergic agonist that reduces sympathetic outflow from the brain, decreasing peripheral vascular resistance and blood pressure. Chlorothiazide is a thiazide diuretic that inhibits sodium and chloride reabsorption in the distal convoluted tubule, increasing urinary output and reducing plasma volume.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between HYDRO-SERP "25" and ALDOCLOR-250 depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of HYDRO-SERP "25" is: Hydrochlorothiazide 25 mg orally once daily in the morning. Maximum 100 mg/day.. The standard adult dose of ALDOCLOR-250 is: 250 mg orally twice daily. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between HYDRO-SERP "25" and ALDOCLOR-250 in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. HYDRO-SERP "25" is classified as Category C. FDA Pregnancy Category D. Use of reserpine in the first trimester is associated with an increased risk of congenital malformations, including neural tube defects and cardiovascular. ALDOCLOR-250 is classified as Category C. FDA Pregnancy Category D. First trimester: Associated with cardiovascular defects (e.g., VSD), neural tube defects, and oral clefts. Second and third trimesters: Fetal nephrotoxici. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.